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WHAT THIS PAPER ADDS
 The study strengthens the need for formal evaluation of lung function with spirometry before selection for elective EVAR of AAA.a r t i c l e i n f o
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Objectives: The aim of this study was to analyse lung function test determinants for long-term mortality
after standard endovascular aneurysm repair (EVAR) for infrarenal abdominal aortic aneurysm (AAA).
Design: Retrospective analysis.
Materials: Three-hundred and four consecutive patients treated electively with EVAR (Zenith stent
grafts, Cook) between May 1998 and February 2006 were prospectively enrolled in a computerised
database.
Methods: The Global Initiative for Chronic Obstructive Lung Diseases (GOLD) guideline was used to grade
the severity of obstructive lung disease. Mortality was checked until 1 December 2010. Median follow-up
time was 68 (interquartile range (IQR) 40e94) months.
Results: The percentage of patients with mild, moderate or severe (grade 3) chronic obstructive
pulmonary disease (COPD) was 9.9%, 23.2% and 7.7%, respectively. In a combined medical severity
assessment, arterial partial pressure of oxygen (PaO2) < 8.0 kPa or COPD, grade 3 (hazard ratio (HR)
2.06; 95% conﬁdence interval (CI) (1.24e3.42)), anaemia (HR 1.72; 95% CI (1.21e2.44)), chronic kidney
disease, stage 3 (HR 1.55; 95% CI (1.08e2.24)) and age 80 years (HR 1.55; 95% CI (1.04e2.31)) were
independently associated with long-term mortality. Lower forced expiratory volume in 1 s (FEV1)
(p ¼ 0.002) and lower forced vital capacity (FVC) (p ¼ 0.003) were independently associated with long-
term mortality.
Conclusions: Our ﬁndings strengthen the need for formal evaluation of lung function with spirometry
prior to proceeding to AAA repair.
 2011 European Society for Vascular Surgery. Published by Elsevier Ltd. All rights reserved.Development of abdominal aortic aneurysm (AAA) and chronic
obstructive pulmonary disease (COPD) are both strongly related to
the effects of smoking, and both disorders may be present simul-
taneously: The prevalence of AAA among patients with COPD has
been estimated to be around 10%1 and the prevalence of COPD
among AAA patients has been found to be above 55%.2 InMalmö-Lund, Skåne Univer-
þ46 455731000; fax: þ46
).
ciety for Vascular Surgery. Publishecomparison with AAA, COPD is a far more serious disease in terms
of morbidity, health-care resources and mortality: COPD affected
210 million people worldwide and caused over 3 million deaths
globally in 2005 (5% of all deaths), recognised as the fourth leading
death cause in the world.3
In this context, preoperative assessment of lung function should
be standardised and equally important as evaluation of cardiac
function. However, there are reports indicating that the presence or
absence of COPD, and the severity of COPD, seems to be a factor that
is often overlooked in the preoperative assessment.4,5 Patients who
are not assessed by spirometry prior to intervention for their AAAd by Elsevier Ltd. All rights reserved.
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seldom included in risk factor analysis. Hence, COPD is an under-
diagnosed and under-reported risk factor in patients with AAA.
Spirometry and arterial blood gas analysis prior to either open
or endovascular repair of AAA have, in our institution, been
a standard for evaluation of lung function. However, the prognostic
capacity of each speciﬁc lung function parameter and the severity
of COPD on long-term all-cause mortality are unclear. The aim
of this study was to analyse lung function test determinants for
long-term mortality after standard endovascular aneurysm repair
(EVAR) with the Zenith bifurcated stent graft for infrarenal AAA.
Methods
Patients
The Vascular Center, Malmö-Lund, is a tertiary referral centre for
patients with vascular disease. This study comprised consecutive
patients who underwent elective, non-fenestrated EVAR (Zenith
stent grafts (Cook Europe A/S, Bjaeverskov, Denmark)) for infrare-
nal non-ruptured AAA between May 1998 and February 2006. The
patients were identiﬁed in the prospective database for endovas-
cular interventions. Complementary data were retrieved from
patient records.
EVAR
In general, anatomical suitability for EVAR included proximal
neck diameter 30 mm, angulation 90 and length 12 mm. For
distal implantation, at least one common iliac artery with a distal
diameter 20 mm was required. The procedure was performed
exclusively with percutaneous technique in 47% of the cases by
using percutaneous closure devices at the femoral access sites.
Spirometry
Spirometry was performed according to the standards of the
European Respiratory Society.7 A spirometer (Mirolab 3000 or
EasyOne) was used under the supervision of a physiotherapist,
employed at the Vascular Center, to measure forced expiratory
volume in 1 s (FEV1) and forced vital capacity (FVC). FEV1% was
deﬁned as FEV1 in relation to predicted normal FEV1 and FVC% as
FVC in relation to predicted normal FVC.8e10 Chronic obstructive
pulmonary disease (COPD) was present if FEV1/FVC < 70% (<65
years) or FEV1/FVC < 65% (65 years). The Global Initiative for
Chronic Obstructive Lung Diseases (GOLD) guidelines was used to
grade (stage) the severity of obstructive lung disease:11 Grade 0:
FEV1/FVC  0.70 and FEV1  80% predicted value and symptoms of
chronic bronchitis. Grade 1 (mild): FEV1/FVC< 0.70 and FEV180%
predicted value. Grade 2 (moderate): FEV1/FVC < 0.70 and
FEV1 < 80% predicted value and FEV1  50% predicted value. Grade
3 (severe): FEV1/FVC < 0.70 and FEV1 < 50% predicted value and
FEV130% predicted value. Grade 4 (very severe): FEV1/FVC< 0.70
and FEV1 < 30% predicted value.
Arterial blood gas test
Arterial blood gas was sampled at rest at the Department of
Clinical Physiology, analysed and respiratory failure was considered
present if the arterial partial pressure of oxygen (PaO2) < 8.0 kPa
(60 mmHg), with or without an arterial partial pressure of carbon
dioxide (PaCO2) > 6.7 kPa (50 mmHg), while breathing air at sea
level.12 A pathological blood gas test was present if PaO2 < 9.4 kPa
or PCO2 > 6.3 kPa.Evaluation of renal function
The CockrofteGault formula includes serum creatinine, age,
weight and gender to calculate glomerular ﬁltration rate (GFR).13
Stages of chronic kidney disease were determined on GFR levels
and the National Kidney Foundation guidelines.14 Stage I is deﬁned
as GFR > 90 ml min1 1.73 m2 (normal or increased GFR), stage II
(GFR 60e89 ml min1 1.73 m2, small decrease in GFR), stage III
(GFR 30e59mlmin11.73m2, moderate decrease in GFR), stage IV
(GFR 15e29 ml min1 1.73 m2, large decrease in GFR) and stage V
(GFR < 15 ml min1 1.73 m2, need for dialysis, end-stage renal
disease).
Other deﬁnitions
Hypertension was deﬁned as systolic blood pressure
>140 mmHg or diastolic blood pressure >90 mmHg, or both, at
admission. Hypertension was also considered if the patient previ-
ously had been diagnosed with hypertension or was taking anti-
hypertensive medication. Cerebrovascular disease was considered
if there was a history of stroke (cerebral bleeding or infarction) or
transient ischaemic attack (TIA). Ischaemic heart disease was
considered if there was a history of myocardial infarction, angina
pectoris, coronary artery bypass graft or percutaneous coronary
angioplasty. Diabetes mellitus was noted if the patient had anti-
diabetic treatment with diet, oral hypoglycaemic agents or insulin.
Smoking included both current and former tobacco smokers.
Anaemia was deﬁned as haemoglobin <134 g l1 in men and
<117 g l1 in women.
Follow-up
All patients were monitored from the day of EVAR until death or
1 December 2010. Median follow-up time was 68 months (inter-
quartile range (IQR) 40e94). Follow-up mortality data were
retrieved from the Swedish Population Registry. The causes of
deaths (death certiﬁcates) were obtained from the National Board
of Health and Welfare. This study was approved by the Research
Ethics Committee at the University of Lund.
Statistical methods
Data management and statistical analysis were performed using
SPSS 17.0 software (SPSS Inc., Chicago, IL, USA). Continuous vari-
ables were expressed asmedian and IQR. Differences in proportions
were evaluated using the chi-square test or Kendall tau-b test.
Comparisons between groups by using continuous variables were
made with the ManneWhitney U test. Correlations were calculated
with the Spearman’s rank test. Variables associated with death
during follow-up in the univariate Cox regression analysis were
further tested in a multivariate Cox regression model. Associations
were expressed in terms of hazard ratios (HRs) with 95% conﬁdence
interval (CI) and p-values.
Survival analysis was performed according to the KaplaneMeier
method with Life table analysis. Log-rank test was used in the
overall comparison of survival curves between patients with COPD,
grade 2, and no COPD/COPD, grade 1. p < 0.05 was considered
signiﬁcant.
Results
Base line characteristics
Median age was 74 years (range: 53e89), and 43 (14%)
were women. COPD was found in 95 out of those 233 patients
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ological blood gas result was found in 38 out of those 169 patients
investigated preoperatively with an arterial blood gas test (Table 2).
The percentage of COPD, hypertension and ischaemic heart disease
among the study patients was 40.8%, 85.2% and 42.1%, respectively,
and the interrelationship of these three co-morbidities among
those 233 spirometry-tested patients are shown in Fig. 1. History of
smoking was documented in 85.4% (223/261) of the patients. There
was an association between history of smoking and COPD
(p¼ 0.004). The three patients with FEV1<1.0 L had all COPD, grade
3. Chronic kidney disease, stage 2, was prevalent in 84.8% of the
patients. The proportion of patients with chronic kidney disease,
stage 1, was 15.3%; stage 2 was 36.1%; stage 3 was 45.0%; stage 4
was 3.3%; and stage 5 was 0.3%. Anaemia was prevalent in 34.8% of
the patients. There was an inverse relation between anaemia and
GFR (r ¼ 0.256; p < 0.001). Diabetes mellitus and cerebrovascular
disease were present in 11% and 15% of the study patients,
respectively.
Mortality
The 30-day mortality rate was 3.0% (9/304). The causes of these
early deaths were heart or multiple-organ failure (n ¼ 8) and
incarcerated groin hernia with intestinal ischaemia (n ¼ 1). The
mortality at 5 years and until end of follow-up was 34.9% (106/304)
and 54.3% (165/304), respectively. The proportion of deaths caused
by vascular and pulmonary diseases was 61% (101/165) and 15%
(25/165), respectively. Ten patients died from lung cancer and 15
from COPD.
Comparison in lung function test results between survivors and non-
survivors
Non-survivors at 5 years of follow-up had a lower FEV1, lower
FEV1%, lower FVC and lower FVC% than survivors (Table 1).
Lung function test results in relation to long-term mortality
A lower FEV1 (p < 0.001) and lower FVC (p < 0.001) were
associated with long-term mortality. The presence of moderate orTable 1
Comparison of preoperative lung function test results prior to EVAR among survi-
vors and non-survivors at ﬁve years of follow-up.
Survivors Non-survivors P
Spirometry
Patients 156 77
FEV1 (L) 2.3 (1.8e2.9) 1.9 (1.5e2.4) <0.001
FEV1/Expected FEV1 (FEV1%) 82 (68e97) 75 (59e91) 0.012
FVC (L) 3.4 (2.9e4.1) 3.0 (2.5e3.6) <0.001
FVC/Expected FVC (FVC%) 77 (65e90) 70 (61e82) 0.009
FEV1/FVC (%) 71 (62e77) 67 (60e78) 0.28
COPD by deﬁnition 57 (37%) 38 (49%) 0.061
Classiﬁcation of COPD
Grade 1 (mild) 15 8
Grade 2 (moderate) 33 22
Grade 3 (severe) 9 8 0.44
Arterial blood gas analysis
Patients 111 58
pH 7.42 (7.40e7.44) 7.43 (7.41e7.45) 0.094
PaCO2 (kPa) 5.2 (4.9e5.5) 5.1 (4.8e5.4) 0.11
PaO2 (kPa) 10.3 (9.6e11.3) 10.1 (9.3e11.0) 0.16
Base excess 1 (0e2) 1 (0e3) 0.84
Standard bicarbonate (mmol) 25 (24e26) 25 (25e27) 0.63
Oxygen saturation
of hemoglobin (%)
96 (95e97) 96 (94e97) 0.11severe COPD and pathological arterial blood gas results were
associated with long-term mortality, when adjusted for follow-up
time in a Cox regression model (Table 2). The survival curves for
patients with COPD, grade2, and no COPD/COPD, grade 1, differed
from each other among the 233 spirometry-tested patients
(p ¼ 0.038) (Fig. 2).
Physiological functions in relation to long-term mortality
In a combined medical severity assessment, PaO2< 8.0 or COPD,
GOLD, grade 3 (HR 2.06; 95% CI (1.24e3.42)), anaemia (HR 1.72;
95% CI (1.21e2.44)), chronic kidney disease, stage 3 (HR 1.55; 95%
CI (1.08e2.24)) and age 80 years (HR 1.55; 95% CI (1.04e2.31))
were independently associated with long-term mortality (Table 2).
When entering COPD, grade 2, instead of COPD, grade 3, in this
four-variable Cox regression analysis, there was a trend that COPD,
grade 2 (HR 1.45; 95% CI (0.99e2.10)), was associated with long-
term mortality. When FEV1, age, GFR and anaemia were entered
in the Cox regression model, lower FEV1 (p ¼ 0.002), higher age
(p ¼ 0.043) and anaemia (p ¼ 0.021) remained as independent
predictors for long-term mortality. When FVC, age, GFR and
anaemia were entered into the model, lower FVC (p ¼ 0.003) and
anaemia (p ¼ 0.020) remained as independent predictors for long-
term mortality.
Discussion
The present study results suggest that severe COPD, low FEV1
and low FVC were the most important predictors for all-cause
mortality. Most importantly, the results also imply that
a moderate COPD seems to be a determinant for adverse long-term
outcome. Indeed, a low FEV1 was found to be the most powerful
predictor of increased long-term mortality in the UK Small Aneu-
rysm Trial.15 A spirometry investigation under the guidance of the
physiotherapists and interpretation of the results is a simple and
prognostic informative tool for the preoperative evaluation of
patients prior to AAA repair. Even though exposure to tobacco
smoking is strongly related to both the development of AAA and
COPD, a substantial part of the patients referred for management of
a large AAA have an undiagnosed COPD at that time point.4 Hence,
a proportion of patients may be newly diagnosed with COPD, and
there may be another window of opportunity towards cessation of
tobacco use, and to medically optimise lung function prior to AAA
repair. Since self-reported smoking status is an unreliable indicator
of smoking habit, the results of a spirometry are likely to provide
a better guide to COPD management and counselling.15 In fact,
fewer prescribed inhalers in COPD patients undergoing elective
open repair of AAA have been shown to be associated with unfav-
ourable outcomes.16
As the present study shows, several other risk factors in the
preoperative assessment were almost equally important as severe
COPD for prediction of long-term mortality. Scoring systems,
including a set of risk factors, have been developed in order to
predict risk of mortality5,17e20 in patients after elective EVAR. The
Glasgow aneurysm scorewas derived from a retrospective study on
patients undergoing open repair of ruptured and non-ruptured
AAA between 1980 and 8921 and this scoring system has recently
been applied in an attempt to predict mid-17 and long-term5
mortality after elective EVAR. In the original study,21 the presence
of pulmonary disease was retrieved from patient charts and not by
spirometry results, and pulmonary disease was not found to be
a signiﬁcant risk factor for perioperative mortality. Hence, the
presence of COPD is not included in the Glasgow aneurysm score
and the inﬂuence of COPD onmortality was therefore not evaluated
in the reports assessing this score.5,17 COPDwas a studied risk factor
Table 2
Evaluation of preoperative lung function test and common risk factors in relation to long-term mortality after EVAR.
Risk factor Mortality Mortality risk estimates at end of follow-up
Univariate Cox
regression analysis
Multivariate Cox
regression analysis
Eligible patients (%) Five years of
follow-up (%)
End of follow-up (%) P-value HR (95% CI) P-value
Spirometry
COPD 95/233 (40.8) 38/95 (40.0) 54/95 (56.8) 0.058
COPD, grade 2 74/233 (31.8) 31/74 (41.9) 44/74 (59.5) 0.040
COPD, grade 3 17/233 (7.3) 8/17 (47.1) 14/17 (82.4) 0.016
FEV1 < 1.0 L 3/233 (1.3) 1/3 (33.3) 3/3 (100) 0.13
Arterial blood gas
PaO2<8.0 kPa 5/167 (3.0) 3/5 (60.0) 5/5 (100) 0.0093
PaO2<9.4 or PaCO2>6.3 kPa 38/169 (22.5) 15/38 (39.5) 28/38 (73.7) 0.031
aPaO2<8.0 kPa or COPD, grade 3 22/257 (8.6) 9/22 (40.9) 18/22 (81.8) 0.005 2.06 (1.24e3.42) 0.005
Common
aAge 80 years 67/304 (22.0) 31/67 (46.3) 48/67 (71.6) <0.001 1.55 (1.04e2.31) 0.031
Women 43/304 (14.1) 17/43 (39.5) 26/43 (60.5) 0.58
Hypertension 259/304 (85.2) 97/259 (37.5) 140/259 (54.1) 0.36
Diabetes Mellitus 33/304 (10.9) 12/33 (36.4) 19/33 (57.6) 0.52
Ischaemic Heart Disease 128/304 (42.1) 45/128 (35.2) 66/128 (51.6) 0.82
Cerebrovascular disease 46/304 (15.1) 16/46 (34.8) 27/46 (58.7) 0.37
aStage 3 Chronic kidney disease 147/302 (48.7) 64/147 (43.5) 96/147 (65.3) <0.001 1.55 (1.08e2.24) 0.019
aAnaemia 105/302 (34.8) 49/105 (46.7) 71/105 (67.6) <0.001 1.72 (1.21e2.44) 0.002
All patients 304 106/304 (34.9) 165/304 (54.3)
a Variables entered in a Cox regression analysis.
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severity of the disease was not done. In this context, it needs to be
emphasised that there is a large difference in predicted survival
between patients withmild and severe COPD as has been suggested
by the results in the present study. After multivariate testing, it was
only the most recent proposed nomogram that has included COPD
for the prediction of long-term survival after EVAR.19 The present
study suggests that severity of COPD or FEV1 or FVC should be
included in such preoperative risk stratiﬁcation models in order to
identify high-risk patients with expected short-term survival. Even
in large aneurysms exceeding 6 cm inmaximal aneurysm diameter,
elective EVAR in patients with severe COPD may seldom be
indicated.22,23
Most patients with COPD have emphysema and the extent of
emphysema increases with increasing severity of COPD.24 Tissue
destruction by emphysema is therefore an important determinant
of disease severity in COPD. In emphysema patients, a higher
prevalence of AAA was found among those with severe COPDCOPD
12 (6%)
3 (1%)
Ischemic
heart disease
6 (3%)42 (19%)38 (18%)
69 (32%)
Hypertension
47 (21%)
Figure 1. Venn diagram showing the associations between hypertension, ischaemic
heart disease and COPD in patients undergoing elective standard EVAR for AAA. At
least one of these three co-morbidities was present in 217 out of the 233 (93%)
spirometry-tested patients.compared to those with moderate COPD.1 A similar relation was
found in the present study, where moderate COPD was more than
twice as common as mild COPD. These ﬁndings imply that patients
with larger aneurysmsmay have amore serious COPD than patients
with smaller aneurysms. The association between lung tissue
destruction that occurs in emphysema and aortic wall degeneration
in aneurysm formation has been a matter of considerable debate.
So far, a degenerative tissue response in various organs secondary
to smoking in susceptible individuals seems to be the most
consistent explanation.Figure 2. Long-term survival after elective EVAR for AAA in Malmö 1998e2006:
Patients with COPD, grade 2 (green line) vs patients with no COPD or COPD, grade 1
(blue line). Censored patients marked with ticks. Numbers below time axis denote
patients at risk in each group at respective time point. Standard Error of cumulative
proportion of survivors at end of interval is shown within parentheses.
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the retrospective design and the proportion of patients with
incomplete data. Missing data are a potential source of bias which
cannot be accounted for. Apart from missing data in the patient
record ﬁles, a proportion of patients did not undergo the stand-
ardised preoperative pulmonary assessment. The logistics might
not have been worked out properly in some patients, especially in
those referred for sub-acute treatment from other hospitals. The
fact that the blood gas analysis test was performed in another
department might have lowered the rate of tested patients. In
addition, it cannot be excluded that other factors such as
unawareness of the work-up regime by junior doctors or ignorance
towards the preoperative pulmonary assessment by some doctors
might have played a role. From the spirometry results obtained, the
proportion of patients with COPD, 40.8%, was most likely under-
estimated in this study since patients with COPD, grade 0 (symp-
toms of chronic bronchitis but no obstruction proven), not could be
evaluated retrospectively.
In conclusion, our ﬁndings strengthen the need for formal
evaluation of lung function with spirometry prior to proceeding to
AAA repair. Patients with severe COPD have an increased risk of
mortality, which must be balanced against risk of rupture of AAA.
Conﬂict of Interest
None.
Funding
None.
References
1 Laarhoven C, Borstlap A, Henegouven D, Palmen F, Verpalen M & Shoemaker M
1993. Chronic obstructive pulmonary disease and abdominal aortic aneurysms.
Eur J Vasc Surg, 7, 386e390.
2 Fowkes FG, Anandan C, Lee A, Smith F, Tzoulaki I & Rumley A, et al. 2006.
Reduced lung function in patients with abdominal aortic aneurysm is associ-
ated with activation of inﬂammation and hemostasis, not smoking or cardio-
vascular disease. J Vasc Surg, 43, 474e480.
3 http://www.who.int/mediacentre/factsheets.
4 Dawson J, Vig S, Choke E, Blundell J, Home G & Downham C, et al. 2007. Medical
optimization can reduce morbidity and mortality associated with elective aortic
aneurysm repair. Eur J Vasc Endovasc Surg, 33, 100e104.
5 Nevala T, Biancari F, Perälä J,Manninen H, Pekka-Sakari A & Matsi P, et al. 2010.
Risk prediction in patients undergoing elective endovascular repair of an
abdominal aortic aneurysm. Scand Cardiovasc J, 44, 125e128.6 Kemp SV, Polkey MI & Shah PC 2009. The epidemiology, etiology, clinical
features and natural history of emphysema. Thorac Surg Clin, 19, 149e158.
7 Quanjer H, Tammeling GJ, Coles JE, Pedersen OF, Peslin R & Yernault J- C 1993.
Lung volumes and forced ventilatory ﬂows. Report working party. Standardi-
zation of Lung function tests. European community for steel and coal. Ofﬁcial
statement of the European Respiratory Society. Eur Respir J, 6, 5e40.
8 Berglund E, Birath G, Bjure J, Grimby G, Kjellmer I & Sandqvist L, et al. 1963.
Spirometric studies in normal subjects. I. Forced expirograms in subjects
between 7 and 70 years of age. Acta Med Scand, 173, 185e192.
9 Birath G, Kjellmer I & Sandqvist L 1963. Spirometric studies in normal subjects.
II. Ventilatory capacity tests in adults. Acta Med Scand, 173, 193e198.
10 Grimby G & Soderholm B 1963. Spirometric studies in normal subjects. III Static
lung volumes and maximum voluntary ventilation in adults with note on
physical ﬁtness. Acta Med Scand, 173, 199.
11 Pauwels RA, Buist AS, Calverley PM, Jenkins CR & Hurd SS 2001. Global strategy
for the diagnosis, management and prevention of chronic obstructive pulmo-
nary disease. NHLBI/WHO Global Initiative for Chronic Obstructive Lung
Disease (GOLD). Workshop summary. Am J Respir Crit Care Med, 163,
1256e1276, http://www.goldcopd.com.
12 Cotes JE 1993. Lung function, assessment and application in medicine. Oxford, UK:
Blackwell.
13 Cockcroft DW & Gault MH 1976. Prediction of creatinine clearance from serum
creatinine. Nephron, 16, 31e41.
14 Abboud H & Henrich W 2010. Stage IV chronic kidney disease. N Engl J Med, 362,
56e65.
15 The UK 2000. Small aneurysm trial participants. Smoking, lung function and
the prognosis of abdominal aortic aneurysm. Eur J Vasc Endovasc Surg, 19,
636e642.
16 Upchurch G, Proctor M, Henke P, Zajkowski P, Riles E & Ascher M, et al. 2003.
Predictors of severe morbidity and death after elective abdominal aortic
aneurysmectomy in patients with chronic obstructive pulmonary disease. J Vasc
Surg, 37, 594e599.
17 Baas AF, Janssen KJ, Prinssen M, Buskens E & Blankensteijn JD 2008. The
Glasgow aneurysm score as a tool to predict 30-day and 2-year mortality in the
patients from the Dutch randomized endovascular aneurysm management
trial. J Vasc Surg, 47, 277e281.
18 Giles K, Schermerhorn M, O’Malley J, Cotterill P, Jhaveri A & Pomposelli F, et al.
2009. Risk prediction for perioperative mortality of endovascular vs open repair
of abdominal aortic aneurysms using the Medicare population. J Vasc Surg, 50,
256e262.
19 Mastracci T, Greenberg R, Hernandez A & Morales C 2010. Deﬁning high risk in
endovascular aneurysm repair. J Vasc Surg, 51, 1088e1095.
20 Barnes M, Boult M, Thompson MM, Holt PJ & Fitridge RA 2010. Personalized
predictions of endovascular aneurysm repair success rates: validating the ERA
model with UK Vascular Institute data. Eur J Vasc Endovasc Surg, 40, 436e441.
21 Samy AK, Murray G & MacBain G 1994. Glasgow aneurysm score. Cardiovasc
Surg, 2, 41e44.
22 Truelsen T, Prescott E, Lange P, Schnohr P & Boysen G 2001. Lung function and
risk of fatal and non-fatal stroke. The Copenhagen City Heart Study. Int J Epi-
demiol, 30, 145e151.
23 Friedman GD, Klatsky AL & Siegelaulb AB 1976. Lung function and risk of
myocardial infarction and sudden cardiac death. N Engl J Med, 294, 1071e1075.
24 Shaker SB, Stavngaard T, Hestad M, Bach KS, Tonnesen P & Dirksen A 2009. The
extent of emphysema in patients with COPD. Clin Respir J, 3, 15e21.
